Biopharma is mobilizing support in Congress for rolling back the new law increasing the discounts required for branded drugs provided to Medicare Part D beneficiaries in the coverage gap from 50% to 70% beginning in 2019.
The discount surprised many in industry when news that it was part of a budget deal being worked out in...






